You are here

Article Text

Article menu
Download PDFPDF
Correspondence
SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment
  1. Beuy Joob1,
  2. Viroj Wiwanitkit2
  1. 1 Medical Center, Sanitation 1 Medical Academic Center, Bangkok, Thailand
  2. 2 Department of Community Medicine, Dr DY Patil University, Pune, Maharastra, India
  1. Correspondence to Dr Beuy Joob, Sanitation 1 Medical Academic Center, Bangkok 10140, Thailand; beuyjoob{at}hotmail.com

https://doi.org/10.1136/annrheumdis-2020-217506

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Inter-relationship between COVID-19 and rheumatic diseases is an interesting topic in clinical rheumatology. We found that article ‘Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies’ is informative. Monti et al suggested for ‘avoiding the unjustifiable preventive withdrawal of DMARDs, which could lead to an increased risk of relapses and morbidity from the chronic rheumatological condition’. 1 Whether standard therapy for rheumatic diseases have any effect on …

    View Full Text

    Footnotes

    • Contributors BJ and VW equally contributed to the work and approved for final submission.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles